| Literature DB >> 35352601 |
Hangping Ge1, Zhan Shi2, Zhiyin Zheng1, Qiuping Zhu2, Lili Hong1, Yu Zhang1, Jianping Shen1, Shu Deng1.
Abstract
A 33-year-old Chinese woman with a history of immune thrombocytopenic purpura presented with heavy menstrual bleeding. She was found to have thrombocytopenia, plasma ADAMTS13 activity of 0%, and positivity for the plasma ADAMTS13 inhibitor. She was diagnosed with the coexistence of thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura. The patient was treated by plasmapheresis, a glucocorticoid, and rituximab. Her platelet level returned to normal, and she was discharged 28 days after admission. The number of plasmapheresis sessions and the timing of rituximab administration may be the key aspects of management of patients with thrombotic thrombocytopenic purpura who have underlying immune dysfunction caused by diseases such as immune thrombocytopenic purpura.Entities:
Keywords: ADAMTS13; Case report; immune thrombocytopenic purpura.; plasmapheresis; rituximab; thrombotic thrombocytopenic purpura; von Willebrand factor
Mesh:
Substances:
Year: 2022 PMID: 35352601 PMCID: PMC8973045 DOI: 10.1177/03000605221085127
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671